Review Article

Role of HLA, KIR, MICA, and Cytokines Genes in Leprosy

Table 2

Associations between HLA class II and leprosy.

PopulationStudy designSample sizePhenotypeSerotype, allele, or haplotypeType of associationP or Pc Ref.

JapaneseCase-control295LL, 74TL, 110 controlsLL/TT
LL
DR2
DRw9
Susceptibility
Resistance
  
[12]

ThaiCase-control32TT, 32 controlsTTDR2
DQw1
Susceptibility
Susceptibility
  
[22]

Korean157LD, 162 controlsLDDR1
DR2
DR9
DR4
DRw53
DQw1
DQw3
Susceptibility
Susceptibility
Susceptibility
Resistance
Resistance
Susceptibility
Resistance
  
  
  
  
  
  
[13]

TurkishCase-control23LL, 27BL, 50 controlsLL/BLDR2Susceptibility [23]

Asian IndianCase-control23TT, 16PTB, 19 controlsTTDRB1 * 15:02 Susceptibility [24]

Indian Case-control138LD, 237 controlsLDDR2
DQw1
DQw7
Susceptibility
Susceptibility
Susceptibility
  
  
[15]
Case-control68LL, 237 controlsLLDR2
DQw1
Susceptibility
Susceptibility
  
Case-control30BL, 237 controlsBLDR9
DQw7
Susceptibility
Susceptibility
  

Indian Case-control28TT, 65LL, 47 controlsLLDRB1 * 15  
DRB1*15:01  
DRB1*07:01  
DRB5*01:01  
DQB1*06:01  
DQA1*01:02  
DQA1*01:03  
DQA1*02:01
Susceptibility
Susceptibility
Susceptibility
Susceptibility
Susceptibility
Susceptibility
Susceptibility
Susceptibility
  
  
  
  
  
  
  
[25]
Case-control28TT, 65LL, 47 controlsTTDRB1 * 15  
DRB1*15:02  
DQB1*0601  
DQB1*05:03
Susceptibility
Susceptibility
Susceptibility
Resistance
  
  
  

IndianCase-control39TT, 20PTB, 46 controlsTTDRB1 * 15:02  
Haplotype:   
DRB1*1501-DRB5*0101-DQA1*0102-DQB1*0502
Susceptibility
Resistance
  
  
[26]

IndianCase-control54TT, 44 controlsTTDRB1 * 15 Susceptibility [27]

JapaneseCase-control38LL/BL, 79LD, 50 controlsBL/LL
LD
DRB1 * 02  
DRB1*12
Susceptibility
Resistance
  
[28]

BrazilianCase-control32TT, 147 controlsTTDR2Susceptibility [29]

JapaneseCase-control93LD, 114 controlsLDDRB1 * 04:05  
DQA1*03  
DQB1*04:01
Resistance
Resistance
Resistance
  
  
[30]

BrazilianTDT73 families (147 sib-pairs)LDDQB1 * 02:01  
DQB1*05:01  
DRB1*7
Resistance
Susceptibility
Resistance
  
  
[31]
TDT73 families (147 sib-pairs)TTDQB1 * 02:01  
DQB1*05:01
Resistance
Susceptibility
  

EgyptianCase-control24LD, 30 controlsLDDR2
DQ1
Susceptibility
Susceptibility
  
[32]

Southern IndianTDT223 ASPTT DRB1 * 15(2)  
DRB1*09
Susceptibility
Resistance
  
[33]

ArgentineanCase-control70LL, 112 controlsLLDQB1 * 02:01  
DQB1*02:02  
DQB1*02:03
Resistance [34]
Case-control19PB, 112 controlsTTDRB1 * 04 Resistance

North IndianCase-control34BT/TT, 79BL/LL, 111 controls BL/LL DRB1 * 15:01 Susceptibility [35]

BrazilianCase-control578LD, 691 controls LDDRB1 * 04  
DRB1*07  
DRB1*10  
DRB1*12  
DRB1*15
Resistance
Resistance
Susceptibility
Resistance
Susceptibility
  
  
  
  
[36]
Euro-BrazilianCase-control578LD, 691 controlsLDDRB1 * 04/NNc  
DRB1*07/NNc
Resistance
Resistance
  
Afro-BrazilianCase-control578LD, 691 controlsLDDRB1 * 10/NNc  
DRB1*15/NNc
Susceptibility
Susceptibility
  
VietnamTDT194 single-case familiesLDDRB1 * 10  
DRB1*04
Susceptibility
Resistance
  

ArgentineanCase-control71LD, 81 controlsLDDRB1 * 14:01  
DRB1*14:06  
DRB1*08:08  
DRB1*11:03
Susceptibility
Susceptibility
Resistance
Resistance
  
  
  
[37]

Chinese Case-control305LD, 527 controlsLDDRB1 * 15  
DRB1*09
Susceptibility
Resistance
  
[38]

BrazilianCase-control30BL, 178 controlsBLDRB1 * 16:01 Susceptibility [39]
Case-control63LL, 43TT LLDRB1 * 08 Susceptibility

TaiwaneseCase-control65LD 190 controlsMLDRB1 * 04:05 Resistance [40]

BrazilianCase-control17LL, 77 controlLLDRB1 * 11 Resistance [41]

BrazilianCase-control36LL, 85 controlLLDRB1 * 16 Susceptibility [42]
Case-control20TT, 85 controlTTDRB1 * 14 Susceptibility

MB: multibacillary leprosy; PB: paucibacillary; LL: lepromatous leprosy; BL: borderline lepromatous; BB: borderline borderline; TT: tuberculoid leprosy; PTB: pulmonary tuberculosis; LD: leprosy disease; NNc: all not significantly different alleles collapsed into a unique group (i.e., DRB1*04, 07, 10, 12, and 15) [36]; ASP: affected sib-pair; ns: not significant; Pc: corrected value; Ref.: reference.